0000019617-12-000201.txt : 20120426 0000019617-12-000201.hdr.sgml : 20120426 20120426163204 ACCESSION NUMBER: 0000019617-12-000201 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20120426 DATE AS OF CHANGE: 20120426 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Syneron Medical Ltd. CENTRAL INDEX KEY: 0001291361 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-80182 FILM NUMBER: 12783933 BUSINESS ADDRESS: BUSINESS PHONE: 972-4-909-6200 MAIL ADDRESS: STREET 1: INDUSTRIAL ZONE STREET 2: P.O.B. 550 CITY: YOKNEAM ILLIT STATE: L3 ZIP: 20692 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: JPMORGAN CHASE & CO CENTRAL INDEX KEY: 0000019617 STANDARD INDUSTRIAL CLASSIFICATION: NATIONAL COMMERCIAL BANKS [6021] IRS NUMBER: 132624428 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 270 PARK AVE STREET 2: 38TH FL CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2122706000 MAIL ADDRESS: STREET 1: 270 PARK AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: J P MORGAN CHASE & CO DATE OF NAME CHANGE: 20010102 FORMER COMPANY: FORMER CONFORMED NAME: CHASE MANHATTAN CORP /DE/ DATE OF NAME CHANGE: 19960402 FORMER COMPANY: FORMER CONFORMED NAME: CHEMICAL BANKING CORP DATE OF NAME CHANGE: 19920703 SC 13G 1 syneronmedical.htm SYNERON MEDICAL LTD. 5:  

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549



 
 

SCHEDULE 13G

(Rule 13d-102)
 
 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)


















Syneron Medical Ltd.

( NAME OF ISSUER )
 
 

COMMON STOCK

(Title of Class of Securities)
 
 

M87245102

(CUSIP Number)
 
 

DECEMBER 30, 2011

(Date of Event Which Requires Filing of this Statement)


















Check the appropriate box to designate the rule pursuant to which this Schedule is filed:


   
X Rule 13d-1 (b)
   
Rule 13d-1 (c)
   
Rule 13d-1 (d)

 



 
CUSIP No. M87245102
13G 
Page 1 of 3 pages



 
1.
Names of reporting persons JPMorgan Chase & Co. 
  I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) 13-2624428

 



 
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) 
    (b) 



 
3.
SEC USE ONLY



 
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
  Delaware

 



 
NUMBER OF
5.
SOLE VOTING POWER 1,685,911
SHARES
     
BENEFICIALLY
6.
SHARED VOTING POWER 986
OWNED BY
     
EACH
7.
SOLE DISPOSITIVE POWER 1,953,684
REPORTING
     
PERSON WITH
8.
SHARED DISPOSITIVE POWER 986

 



 
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    1,954,670



 
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES  
  CERTAIN SHARES  

 



 
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
  5.5%

 



 
12.
TYPE OF REPORTING PERSON* HC

 


Item 1(a). Name of Issuer:
  Syneron Medical Ltd.
Item 1(b). Address of Issuer's Principal Executive Offices:
  Industrial Zone, Yokneam Illit, 20692, Tavor Building P.O.B. 550, Israel
 
Item 2(a). Name of Person Filing:
  JPMorgan Chase & Co. 
Item 2(b). Address of Principal Business Office or, if None, Residence:
  270 PARK AVE
  NEW YORK, NY 10017
Item 2(c). Citizenship
  Delaware
Item 2(d). Title of Class of Securities:
  COMMON STOCK 
  Unless otherwise noted, security being reported is common stock
Item 2(e). CUSIP Number: M87245102
Item 3 If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b)
  Or (c), Check Whether the Person Filing is a :
 
(a)
Broker or dealer registered under Section 15 of the Exchange Act;
 
(b)
Bank as defined in Section 3(a)(6) of the Exchange Act;
 
(c)
Insurance company as defined in Section 3(a)(19) of the
      Exchange Act;
 
(d)
Investment company registered under Section 8 of the Investment
      Company Act;
 
(e)
An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
 
(f)
An employee benefit plan or endowment fund in accordance with
      Rule 13d-1(b)(1)(ii)(F);
 
(g)
X
A parent holding company or control person in accordance with
      Rule 13d-1(b)(1)(ii)(G);
 
(h)
A savings association as defined in Section 3(b) of the Federal
      Deposit Insurance Act;
 
(i)
A church plan that is excluded from the definition of an 
      Investment company under Section 3(c)(14) of the Investment 
      Company act;
 
(j)
Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
If this statement is filed pursuant to Rule 13d-1(b), check this box.
X

 


Page 2 of 3 pages


Item 4. Ownership
  Provide the following information regarding the aggregate number and
  Percentage of the class of securities of issuer identified in Item 1.
 
(a)
Amount beneficially owned: 1,954,670
    Including 0 shares where there is a Right to Acquire.
 
(b)
Percent of class: 5.5%
 
(c)
Number of shares as to which such person has:
   
(i)
Sole power to vote or to direct the vote: 1,685,911 
   
(ii)
Shared power to vote or to direct the vote: 986
   
(iii)
Sole power to dispose or to direct the disposition of: 1,953,684
   
(iv)
Shared power to dispose or to direct the disposition of: 986

 
 
Item 5. Ownership of Five Percent or Less of a Class. NOT APPLICABLE
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more
than five percent of the class of securities, check the following. ( )

 
 
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
JPMorgan Chase & Co. is the beneficial owner of 1,954,670 shares of the
issuer's common stock on behalf of other persons known to have one or more of
the following:
  the right to receive dividends for such securities;
  the power to direct the receipt of dividends from such securities;
  the right to receive the proceeds from the sale of such securities;
  the right to direct the receipt of proceeds from the sale of such securities;
No such person is known to have an interest in more than 5% of the class of
securities reported herein unless such person is identified below.

 
 
Item 7. Identification and Classification of the Subsidiary Which Acquired the
  Security being reported on by the Parent Holding Company.
This notice is filed on behalf of JPMorgan Chase & Co. and its wholly owned
Subsidiary (ies),
J.P. Morgan Investment Management Inc. 
JPMorgan Asset Management (UK) Ltd. 
JPMorgan Chase Bank, National Association

 
 
Item 8. Identification and Classification of Members of the Group.
  Not Applicable

 
 
Item 9. Notice of Dissolution of Group.
  Not Applicable

 
 
Item 10. Certifications

 
 
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and are not held for the
purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.

 
 
 


Page 3 of 3 pages



 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the
information set forth in this statement is true, complete and correct.

Dated: APRIL 26,2012 
JPMorgan Chase & Co.
 
By: /s/ Margaret R. Rubin
 
--------------------------------------
 
Margaret R. Rubin
 
Corporate Compliance

 
 
 
 
 
 
 
 
The original statement shall be signed by each person on whose behalf the statement
is filed or his authorized representative. If the statement is signed on behalf of
a person by his authorized representative (other than an executive officer or general
partner of the filing person), evidence of the representative's authority to sign on
behalf of such person shall be filed with the statement, provided, however, that a 
power of attorney for this purpose which is already on file with the commission may
be incorporated by reference. The name and any title of each person who signs the
the statement shall be typed or printed beneath his signature.